William Burns

William Matt Burns is currently Chairman at Vestergaard Frandsen SA since 2017, Chairman at Vestergaard SARL, Independent Non-Executive Vice Chairman at Mesoblast Ltd. since 2016, Chairman at Molecular Partners AG since 2018, Chairman at Okairos SRL, Chairman at Health Innovation Challenge Fund, Chairman at Molecular Partners, Inc. since 2018, Trustee at The Institute of Cancer Research: Royal Cancer Hospital since 2014, and Advisor at Healthcare Royalty Management LLC since 2020.
Former roles include Chief Executive Officer at Roche Pharmaceuticals, Inc. from 2004 to 2009, Chief Executive Officer-Pharmaceuticals Division at Roche Group from 2000 to 2004, Chairman at Biotie Therapies Oy from 2014 to 2016, Director at Genentech, Inc. from 2004 to 2014, Non-Executive Director at Roche Holding AG from 2010 to 2014, Director at F.
Hoffmann-La Roche Ltd. from 2010 to 2014, Senior Independent Non-Executive Director at Shire Plc from 2016 to 2018, Non-Executive Director at Chugai Pharmaceutical Co., Ltd. from 2013 to 2014, Senior Independent Director at Shire Pharmaceuticals, Inc. from 2016 to 2018, Non-Executive Director at Shire Group Plc from 2010 to 2018, Member-Governors Board at The Wellcome Trust Ltd. from 2016 to 2020, Member-Supervisory Board at Crucell NV from 2010 to 2011, and Chairman at Masters Pharmaceuticals Ltd., Interpharma, Okairos AG, and Director at International Federation of Pharmaceutical Manufacturers and European Federation of Pharmaceutical Industries & Assns.
Education includes undergraduate studies at the University of Strathclyde.